Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury

Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antith...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CNS Neurosci Ther
Autors principals: Lee, Jeong Hyun, Park, So Youn, Shin, Hwa Kyoung, Kim, Chi Dae, Lee, Won Suk, Hong, Ki Whan
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Inc 2008
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494013/
https://ncbi.nlm.nih.gov/pubmed/18482026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2008.00042.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars